Author

Matthew Pierpoint

Duke Medical CenterORCID 0000-0002-6171-7086Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:clustering· 1

Frequent Co-Authors

Amy J. WisdomiD· 2 shared David G. KirschiD· 2 shared Lixia LuoiD· 2 shared Warren FloydiD· 2 shared Yan MaiD· 2 shared Ajay SubramanianiD· 1 shared Alexander L. LazaridesiD· 1 shared Brendan Craig DicksoniD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Amy J. WisdomORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyiSciencePeer-reviewedApr 4, 2025

Loss of function of Atrx leads to activation of alternative lengthening of telomeres in a primary mouse model of sarcoma

Matthew Pierpoint, Warren Floyd, Amy J. Wisdom…·David G. Kirsch

This study shows that loss of Atrx in a mouse sarcoma model activates the ALT telomere maintenance pathway independently of telomerase, leading to telomere instability and APB formation.

6 citations

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyInternational Journal of Radiation Oncology*Biology*PhysicsPeer-reviewedSep 27, 2024

Enhancing radiotherapy response via intratumoral injection of the TLR9 agonist CpG to stimulate CD8 T cells in an autochthonous mouse model of sarcoma

Chang Su, Collin L. Kent, Matthew Pierpoint…·David G. Kirsch

This study shows that combining radiotherapy with CpG, a TLR9 agonist, enhances tumor response in a mouse sarcoma model by boosting CD8 T cell activity.

3 citations

mousebulk RNA-seq

𝕏 PostBluesky